J. Nicholas O’Donnell

Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model

Thomas P. Lodise, Nicolas M Smith, J. Nicholas O’Donnell et al. · Journal of Antimicrobial Chemotherapy · 2020 · 80 citations · Full text

Pharmacy, Infectious Diseases, Microbiology +17

Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats

Nathaniel J. Rhodes, Walter C. Prozialeck, Thomas P. Lodise et al. · Antimicrobial Agents and Chemotherapy · 2016 · 69 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury

Gwendolyn Pais, Sean N. Avedissian, J. Nicholas O’Donnell et al. · Antimicrobial Agents and Chemotherapy · 2019 · 62 citations · Full text

Medicine, Nephrology, Pharmacology +16

24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury

J. Nicholas O’Donnell, Nathaniel J. Rhodes, Thomas P. Lodise et al. · Antimicrobial Agents and Chemotherapy · 2017 · 54 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model

Sean N. Avedissian, Gwendolyn Pais, J. Nicholas O’Donnell et al. · Journal of Antimicrobial Chemotherapy · 2019 · 53 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16